Cara Therapeutics (CARA) Tops Q1 EPS by 2c

Cara Therapeutics (NASDAQ: CARA) reported Q1 EPS of ($0.49), $0.02 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $6.17 million versus the consensus estimate of $4.95 million.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Hermès can regain momentum despite China weakness, Jefferies says